CLNN

Clene Inc. [CLNN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CLNN Stock Summary

Top 10 Correlated Stocks

CLNN


In the News

02:19 29 Mar 2024 CLNN

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?

10:31 29 Mar 2024 CLNN

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.

05:02 29 Mar 2024 CLNN

7 Underappreciated Penny Stocks That Pack a Wallop

Let's be brutally honest with each other – underappreciated penny stocks are that way for a reason. I'm not going to say they stink but they're incredibly unpredictable.

04:00 29 Mar 2024 CLNN

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis, today announced that it will participate in the Cantor Fitzgerald Annual Global Healthcare Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will be participating in the presentation and 1x1 investor meetings.

08:20 29 Mar 2024 CLNN

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis, today announced that it will participate in the following investor conferences in September.

07:00 29 Mar 2024 CLNN

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will participate in the presentation and investor meetings.

01:20 29 Mar 2024 CLNN

10 Top Penny Stocks To Watch Right Now For Under $1

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

07:01 29 Mar 2024 CLNN

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago.

09:58 29 Mar 2024 CLNN

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

04:10 29 Mar 2024 CLNN

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9

CLNN Financial details

Company Rating
Neutral
Market Cap
57.02M
Income
-51.61M
Revenue
654K
Book val./share
0.1
Cash/share
0.27
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-1.64
Forward P/E
-1.53
PEG
-0.11
P/S
74.94
P/B
2.51
P/C
1.58
P/FCF
-1.65
Quick Ratio
2.83
Current Ratio
3.04
Debt / Equity
2.04
LT Debt / Equity
0.53
-
-
EPS (TTM)
-0.57
EPS next Y
-0.28
EPS next Q
-0.08
EPS this Y
104.35%
EPS next Y
-50.35%
EPS next 5Y
-188.91%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
57.41%
EPS Q/Q
321.28%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
25.08%
Inst Trans
0.59%
ROA
-54%
ROE
-295%
ROC
-0.9%
Gross Margin
87%
Oper. Margin
-5677%
Profit Margin
-4571%
Payout
-1%
Shs Outstand
128.43M
Shs Float
67.95M
-
-
-
-
Target Price
10
52W Range
0.25-1.22
52W High
-
52W Low
-
RSI
52
Rel Volume
0.24
Avg Volume
966.67K
Volume
231.52K
Perf Week
6.75%
Perf Month
-7.19%
Perf Quarter
-20.93%
Perf Half Y
-7.97%
-
-
-
-
Beta
0.483
-
-
Volatility
0.01%, 0.03%
Prev Close
0.47%
Price
0.427
Change
1.67%

CLNN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.010.010.01
Net income per share
-0.94-1.1-0.16-0.23-0.47
Operating cash flow per share
-0.76-1.08-0.56-0.6-0.29
Free cash flow per share
-0.78-1.1-0.58-0.68-0.29
Cash per share
0.513.390.820.360.33
Book value per share
-3.90.020.20.050.13
Tangible book value per share
-3.90.020.20.050.13
Share holders equity per share
-3.90.020.20.050.13
Interest debt per share
0.170.30.40.540.3
Market cap
181.91M189.39M252.39M65.2M31.12M
Enterprise value
176M134.44M226.14M78.7M34.46M
P/E ratio
-11.18-9.82-25.91-4.27-0.63
Price to sales ratio
0919.38349.09137.8547.59
POCF ratio
-13.78-10.01-7.29-1.67-1.03
PFCF ratio
-13.48-9.8-7.02-1.48-1.02
P/B Ratio
-2.68555.4120.0420.142.32
PTB ratio
-2.68555.4120.0420.142.32
EV to sales
0652.63312.79166.3852.7
Enterprise value over EBITDA
-11.85-8.4-4.76-1.75-0.89
EV to operating cash flow
-13.34-7.1-6.53-2.02-1.14
EV to free cash flow
-13.05-6.96-6.29-1.78-1.13
Earnings yield
-0.09-0.1-0.04-0.23-1.59
Free cash flow yield
-0.07-0.1-0.14-0.68-0.98
Debt to equity
-0.0412.681.919.832.04
Debt to assets
0.190.060.380.720.52
Net debt to EBITDA
0.43.430.55-0.3-0.09
Current ratio
2.25.49.062.111.53
Interest coverage
-185.59-17.9-52.04-13.75-8.89
Income quality
0.820.983.551.30.61
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
02526.0235.8120.03
Research and developement to revenue
073.8139.367.4838.56
Intangibles to total assets
00000
Capex to operating cash flow
0.020.020.040.130.01
Capex to revenue
0-1.88-1.84-10.95-0.5
Capex to depreciation
-0.35-0.4-1.39-5.08-0.19
Stock based compensation to revenue
03.6917.131813.94
Graham number
9.070.690.850.511.16
ROIC
0.26-2.47-1.04-0.56-0.89
Return on tangible assets
-1.09-0.28-0.15-0.34-0.95
Graham Net
-4.23-0.390.02-0.27-0.03
Working capital
5.16M51.32M48.56M15.34M13.52M
Tangible asset value
-67.77M341K12.6M3.24M13.39M
Net current asset value
-73.17M-4.91M4.12M-12.06M-99K
Invested capital
-0.0412.681.919.832.04
Average receivables
01.39M1.89M901K763.5K
Average payables
01.01M1.52M2.47M2.26M
Average inventory
0109.5K116K42K40K
Days sales outstanding
03.84K814.31145.85746.74
Days payables outstanding
360.546.31K2.43K42.31K300.64
Days of inventory on hand
11.361.07K51.78603.657.4
Receivables turnover
00.090.452.50.49
Payables turnover
1.010.060.150.011.21
Inventory turnover
32.140.347.050.649.35
ROE
0.24-56.53-0.77-4.72-3.7
Capex per share
-0.02-0.02-0.02-0.080

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.13-0.18-0.29-0.02-0.08
Operating cash flow per share
-0.12-0.12-0.08-0.05-0.06
Free cash flow per share
-0.14-0.12-0.08-0.05-0.06
Cash per share
0.360.240.570.330.27
Book value per share
0.05-0.020.250.170.1
Tangible book value per share
0.05-0.020.250.170.1
Share holders equity per share
0.05-0.020.250.170.1
Interest debt per share
0.50.440.380.240.22
Market cap
65.2M85.94M75.72M63.68M38.09M
Enterprise value
78.7M99.85M58.15M53.48M41.43M
P/E ratio
1.89-1.55-0.75-6.58-0.94
Price to sales ratio
278.65803.14281.5589.6224.06
POCF ratio
-8.45-9.32-10.79-9.42-5.28
PFCF ratio
-6.92-9.05-10.85-9.35-5.25
P/B Ratio
20.14-52.823.522.972.84
PTB ratio
20.14-52.823.522.972.84
EV to sales
336.31933.19216.16495.17243.71
Enterprise value over EBITDA
-7.71-9.75-2.4-5.6-4.36
EV to operating cash flow
-10.2-10.83-8.28-7.91-5.74
EV to free cash flow
-8.36-10.52-8.33-7.86-5.71
Earnings yield
0.13-0.16-0.33-0.04-0.27
Free cash flow yield
-0.14-0.11-0.09-0.11-0.19
Debt to equity
9.83-19.891.471.492.04
Debt to assets
0.720.810.470.530.52
Net debt to EBITDA
-1.32-1.360.731.07-0.35
Current ratio
2.111.479.313.041.53
Interest coverage
-11.84-9.53-9.368.03-8.28
Income quality
7.320.780.282.80.71
Dividend Yield
00000
Payout ratio
000-0.080
Sales general and administrative to revenue
18.1929.7212.8833.9419.29
Research and developement to revenue
33.2169.1124.5955.337.16
Intangibles to total assets
00000
Capex to operating cash flow
0.220.03-0.010.010.01
Capex to revenue
-7.27-2.60.14-0.44-0.26
Capex to depreciation
-5.6-0.690.09-0.11-0.1
Stock based compensation to revenue
8.6720.789.1122.1912.04
Graham number
0.380.31.280.270.43
ROIC
2.13-0.33-0.08-0.13-0.22
Return on tangible assets
0.19-0.35-0.37-0.04-0.19
Graham Net
-0.24-0.270.040.03-0.02
Working capital
15.34M7.95M47.64M31.18M13.52M
Tangible asset value
3.24M-1.63M21.53M21.41M13.39M
Net current asset value
-12.06M-16.69M7.06M7.42M-99K
Invested capital
9.83-19.891.471.492.04
Average receivables
2.35M3.04M2.07M1.08M1.24M
Average payables
3.23M1.81M727K1.37M1.7M
Average inventory
40.5K65.5K70K78K70.5K
Days sales outstanding
1.14K2.62K340.93956.67708.35
Days payables outstanding
38.75K10.94K1.15K14.17K294.26
Days of inventory on hand
552.861.58K70.917807.24
Receivables turnover
0.080.030.260.090.13
Payables turnover
00.010.080.010.31
Inventory turnover
0.160.061.270.1212.43
ROE
2.668.53-1.17-0.11-0.76
Capex per share
-0.030000

CLNN Frequently Asked Questions

What is Clene Inc. stock symbol ?

Clene Inc. is a US stock , located in Salt lake city of Ut and trading under the symbol CLNN

Is Clene Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10

What is CLNN stock prediction ?

What is Clene Inc. stock quote today ?

Clene Inc. stock price is $0.427 today.

Is Clene Inc. stock public?

Yes, Clene Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap